Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
12.67
-0.50 (-3.80%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now
February 28, 2023
These two high-yield dividend stocks are trading at bargain-basement prices.
Via
The Motley Fool
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
February 21, 2023
Via
Benzinga
Zoetis Stock Shows Rising Relative Strength Upgrades
February 17, 2023
Zoetis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.
Via
Investor's Business Daily
Is This the Telltale Sign to Sell Novavax Stock?
February 14, 2023
You won't find Novavax's latest bad news trumpeted in a press release.
Via
The Motley Fool
NeurAxis: Should You Buy This IPO?
February 08, 2023
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.
Via
Talk Markets
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
February 06, 2023
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.
Via
Talk Markets
Current Report: Takeda Pharmaceutical (TAK)
January 23, 2023
In the past year, Takeda’s share price increased by $1.73, or about 12%.
Via
Talk Markets
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
January 23, 2023
Via
Benzinga
A Bullish Sign Appears On Takeda Pharmaceutical's Chart
December 28, 2022
Via
Benzinga
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
December 13, 2022
Via
Benzinga
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
February 02, 2023
Via
Benzinga
7 Sorry Dividend Stocks to Sell in February Before It’s Too Late
January 30, 2023
These dividend stocks to sell have weak underlying fundamentals, offering little upside potential ahead for investors.
Via
InvestorPlace
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
January 28, 2023
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...
Via
Talk Markets
Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce
January 24, 2023
Via
Benzinga
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
January 14, 2023
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch...
Via
Talk Markets
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
November 23, 2022
Via
Benzinga
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
October 27, 2022
Via
Benzinga
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
January 09, 2023
Via
Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies
December 14, 2022
Via
Benzinga
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
December 09, 2022
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study
Via
Benzinga
Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?
November 30, 2022
Tech layoffs are in the news, but life sciences companies seem to be doing better.
Via
The Motley Fool
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
November 29, 2022
The company says it plans soon to present Phase 2 results and its Phase 3 study design.
Via
Investor's Business Daily
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
November 22, 2022
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...
Via
Benzinga
Why Puma Biotechnology's Shares Jumped 20% on Monday
November 21, 2022
It may have benefited from positive news about another company's drug candidate.
Via
The Motley Fool
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
November 17, 2022
Via
Benzinga
2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade
November 16, 2022
Is now the time to load up on these high-yielding investments?
Via
The Motley Fool
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
November 02, 2022
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.
Via
The Motley Fool
7 Dividend Stocks to Sell Pronto Before a Painful Downturn
October 24, 2022
Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield.
Via
InvestorPlace
Earnings Scheduled For October 27, 2022
October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.